Principle Investigator: Marwan Ghabril, MD
Duration: 72 week treatment period with 4 week screening and 4 week follow-up
Patient Population: Adults with cirrhosis and no history of hepatic encephalopathy
Drug(s): Rifaximin SSD/placebo
Interested in this study? Please contact the clinical liver research team: iuliverr@iu.edu
Enrolling: No
Principle Investigator: Raj Vuppalanchi, MD
Duration: 52 week treatment period with possibility of 52 additional weeks.
Patient Population: Patients 18-75 years old with NASH cirrhosis and no varices.
Drug(s): Belapectin every 2 week infusion.
Interested in this study? Please contact the clinical liver research team: iuliverr@iu.edu
Enrolling: Yes
Principle Investigators: Marwan Ghabril, MD and Eric Orman, MD
Duration: 1 visit
Patient Population: Adults over the age of 18 with a diagnosis of cirrhosis admitted to the ICU, PCU and wards as an inpatient.
Interested in this study? Please contact the clinical liver research team: iuliverr@iu.edu
Enrolling: Yes
Principle Investigator: Raj Vuppalanchi, MD
Duration: 16 weeks
Patient Population: Patients over the age of 18 with a diagnosis of NASH cirrhosis with a BMI >30kg/m2.
Interested in this study? Please contact the clinical liver research team: iuliverr@iu.edu
Principle Investigator: Raj Vuppalanchi, MD
Duration: 5 years
Patient Population: Adults over the age 18 with a diagnosis of cirrhosis admitted to the ICU.
Interested in this study? Please contact the clinical liver research team: iuliverr@iu.edu
Principle Investigator: Niharika Samala, MD
Duration: 2 years (estimated - until 50 patients are enrolled)
Patient Population: Age-matched males and females with NASH cirrhosis; Females must be post-menopausal
Interested in this study? Please contact the clinical liver research team: iuliverr@iu.edu
Enrolling: No
Principle Investigator: Eric Orman, MD
Duration: TBD
Patient Population: Inpatient patients diagnosed with cirrhosis.
Interested in this study? Please contact the clinical liver research team: iuliverr@iu.edu
Enrolling: Yes
Principle Investigator: Eric Orman, MD
Duration: 4 years
Patient Population: Patients with cirrhosis and hepatic encephalopathy taking lactulose
Interested in this study? Please contact the clinical liver research team: iuliverr@iu.edu
Developed by our Clinical Liver Research Investigators, this online calculator is an online resource.
Check out the MCC calculator here.
Enrolling: No
Principle Investigator: Eric Orman, MD
Duration: 1 year
Patient Population: Patients with refractory ascites
Drug(s): Terlipressin
Enrolling: No
Principle Investigator: Craig Lammert, MD
Duration: 1 visit
Patient Population: Alcoholic liver cirrhosis, no viral hepatitis, pre/post-transplant
Enrolling: No
Principle Investigator: Archita Desai, MD
Duration: 3-5 years
Patient Population: Inpatients over the age of 18 with cirrhosis.
Enrolling: No
Principle Investigator: Marwan Ghabril, MD
Duration: 24 week treatment period with 4 week screening and 4 week follow-up
Patient Population: Adults with cirrhosis and history of hepatic encephalopathy
Drug(s): AXA1665/Placebo
Enrolling: No
Principle Investigator: Kavish Patidar, DO
Duration: 5 years
Patient Population: Adults over the age of 18 with a diagnosis of cirrhosis admitted to the ICU.
Principle Investigator: Eric Orman, MD
Duration: 3 months
Patient Population: 18 and older
Enrolling: No
Principle Investigator: Eric Orman, MD
Duration: Patients are enrolled for 6 months - total study duration is 2 years.
Patient Population: Patients with cirrhosis who have recently been discharged from the hospital and their caregivers.
